340B Drug Pricing Program
Motion and Memorandum in Support of Motion to Intervene NOVO NORDISK v Cochran (March 2, 2021)
AHA urges the Department of Health and Human Services (HHS) to ensure hospitals currently participating in the 340B Drug Pricing Program continue to have access to the program despite changes in their payer mix as a result of the COVID-19 public health emergency (PHE).
IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY
Government鈥檚 Opposition to Motion to Intervene - AstraZeneca v. Cochran (March 12, 2021)
AstraZeneca鈥檚 Opposition to Motion to Intervene (March 12, 2021) Insert
Associations鈥 Reply in Support of Motion to Intervene - AstraZeneca v. Cochran (March 19, 2021)
黑料正能量 Association, 340B Health, America鈥檚 Essential Hospitals, Association of American Medical Colleges, National Association of Children鈥檚 Hospitals d/b/a Children鈥檚 Hospital Association, and American Society of HealthSystem Pharmacists (collectively the 鈥淧roposed Intervenors鈥) move鈥
Response to Motion to Intervene - SANOFI-AVENTIS vs HHS (March 22, 2021)
UNITED STATES DISTRICT COURT
FOR THE SOUTHERN DISTRICT OF INDIANA
INDIANAPOLIS DIVISION
ELI LILLY AND COMPANY,
Lilly Corporate Center
893 Delaware Street
Indianapolis, IN 46225, et al.,